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1 Tedisamil is a bradycardiac agent that prolongs the QT interval of the ECG and prevents cardiac
arrhythmias. Given this pro®le, tedisamil might be expected to have proarrhythmic actions similar to
Class III antiarrhythmic drugs. To address this question, the actions of dofetilide and tedisamil were
examined in rabbit isolated hearts in which bradycardia was induced by AV ablation.
2 The QT interval was prolonged in a reverse rate-dependent fashion by dofetilide (3 and 30 nM)
and tedisamil (0.3 and 3 mM).
3 Torsades de pointes was observed in 1/7 hearts treated with 3 nM dofetilide and 0/7 hearts
treated with 0.3 mM tedisamil. The incidence of torsades de pointes was increased to 5/7 in hearts
treated with 30 nM dofetilide and to 7/7 in hearts treated with 3 mM tedisamil (both P50.05 vs
control).
4 The actions of 30 nM dofetilide and 3 mM tedisamil were also examined in hearts paced at 50,
100, 200 and 50 beats min71 successively. Both drugs caused torsades de pointes in 5/5 hearts paced
at 50 beats min71; however, the incidence was reduced to 0/5 during pacing at 200 beats min71.
Thus, drug-induced proarrhythmia was bradycardia-dependent.
5 Drug-induced prolongation of the interval between the peak and end of the T-wave (QTa-e) was
reverse rate-dependent and was associated with the occurrence of torsades de pointes (r=0.91,
P50.01).
6 The results suggest that tedisamil, like dofetilide, presents a risk for development of torsades de
pointes.
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Introduction
There is a continuing need for antiarrhythmic drugs that are
both safe and eective. Drugs classed by the Vaughan-
William's scheme as Class III prolong cardiac action
potentials and, therefore, the QT interval of the ECG. It is
clear that this class of drugs can have useful antiarrhythmic
actions; however, the proarrhythmic actions of such drugs
severely limit their utility. For example, ibutilide (Stambler et
al., 1997; Oral et al., 1999), dofetilide (Frost et al., 1997;
Torp-Pedersen et al., 1999) and sotalol (Kehoe et al., 1990)
are associated with a signi®cant risk of torsades de pointes.
In contrast, the risk of torsades de pointes with amiodarone
is regarded as being low despite its Class III pro®le
(Connolly, 1999). Unfortunately, pulmonary toxicity limits
the use of this drug to high-risk patients. Consequently, there
is a continuing need for antiarrhythmic drugs.
Tedisamil is an experimental bradycardic agent being
developed for the treatment of angina pectoris (Fox et al.,
2000). The drug prolongs cardiac action potentials and the
QT interval of the ECG in experimental animals (Beatch et
al., 1991; Tsuchihashi & Curtis, 1991; Rees et al., 1993;
Wallace et al., 1995; Chi et al., 1996) and in man (Bargheer et
al., 1994; Fox et al., 2000). Tedisamil brings about these
eects via blockade of several cardiac ion currents. These
include the delayed recti®er K+ current (Dukes & Morad,
1989; Dukes et al., 1990), transient outward current (Dukes
& Morad, 1989; Dukes et al., 1990), the ATP-dependent K+
current (Bray & Quast, 1992) as well as the fast inward
sodium current (Beatch et al., 1991; Nemeth et al., 1996) and
the cyclic AMP-activated Cl7 current (Faivre et al., 1998).
Experimental studies have demonstrated that tedisamil has
antiarrhythmic actions in vitro (Tsuchihashi & Curtis, 1991;
Chi et al., 1996) and in vivo against arrhythmias arising from
the atrium (Fischbach et al., 1999) and ventricle (Beatch et
al., 1991; Friedrichs et al., 1996; 1998).
Despite its demonstrated antiarrhythmic eectiveness, it is
not clear if tedisamil carries with it a similar risk of torsades
de pointes to that observed with Class III antiarrhythmic
drugs. The aim of the present study was to examine the
actions of tedisamil under conditions where torsades de
pointes might be expected to occur (i.e., bradycardia and low
[K+]) in a rabbit isolated heart model. The QT prolonging
British Journal of Pharmacology (2001) 132, 1493 ± 1500 ã 2001 Nature Publishing Group All rights reserved 0007 ± 1188/01 $15.00
www.nature.com/bjp
*Author for correspondence; E-mail: benluc@umich.edu
and proarrhythmic actions of tedisamil were compared to
dofetilide. Dofetilide is known to prolong the QT interval of
the ECG and precipitate torsades de pointes in experimental
animals (Buchanan et al., 1993; Bril et al., 1996) and man
(Frost et al., 1997; Torp-Pedersen et al., 1999).
Methods
Guidelines for animal research
The procedures used in this study were in accordance with
the guidelines of the University of Michigan Committee on
the Use and Care of Animals. Veterinary care was provided
by the University of Michigan Unit for Laboratory Animal
Medicine. The University of Michigan is accredited by the
American Association of Accreditation of Laboratory
Animals Health Care, and the animal care use program
conforms to the standards in The Guide for the Care and
Use of Laboratory Animals, Department of Health, Educa-
tion, and Welfare Publication Number (National Institute of
Health) 86-23.
General preparation
Male, New Zealand White rabbits (2 ± 3 kg), were stunned by
cervical dislocation. The heart was rapidly removed and
mounted on a Langendor apparatus. Hearts were perfused
with a modi®ed Krebs-Henseleit buer at a constant ¯ow of
20 ± 30 ml min71 such that the coronary perfusion pressure
was 50 ± 70 mmHg. The composition of the buer (in mM)
was: CaCl2 1.8, KCl 2.8, KH2PO4 1.2, MgSO4 0.83, NaCl
118, NaHCO3 24.88, Na pyruvate 2 and glucose 5.55. The
®nal [K+] was 4 mM. The buer was bubbled continuously
with 95% O2/5% CO2. The heart was maintained at a
constant temperature of 378C using a circulating water bath.
An incision was made in the right atrium and the AV node
was ablated using forceps. This procedure produced rapid
and irreversible AV block and resulted in a low ventricular
rate. Pacing leads were inserted into the intraventricular
septum and, in the event that heart rate fell below 50 beats
min71, pacing was initiated at this rate. The average resulting
ventricular rate was 50+2 beats min71. An incision was
made in the left atrium to allow insertion of a temperature
probe and a balloon into the left ventricle. The intraven-
tricular balloon was ®lled with saline to give an end diastolic
pressure of 5 mmHg. A volume conducted ECG was
recorded as described by Zabel et al. (1997). This permitted
simulated leads V1, V3, V5 and lead II to be recorded
simultaneously. The ECG leads, coronary perfusion pressure
and left ventricular pressure were monitored using Grass
Instruments data acquisition hardware (Models 15AX54 and
15AX12, Quincy, MA, U.S.A.) and Polyview software
(version 2.1, Grass Instruments, Quincy, MA, U.S.A.).
Hearts were allowed 20 min to equilibrate before starting
the experiment.
Experimental protocol for concentration-response studies
The protocol was adapted from that described by Johna et
al. (1998). Hearts were monitored for 5 min before starting
an infusion of vehicle control (0.2% dimethylsulphoxide
dissolved in buer) into a sidearm on the perfusion
apparatus. The infusion rate was 20 ± 30 ml h71 (i.e., 1/
60th of the coronary ¯ow rate). After 20 min, the perfusate
was switched to a low potassium buer ([K+] 3 mM) for
5 min. Thereafter, the heart was perfused with normal buer
([K+]4 mM) for 5 min. To assess rate-dependent changes in
the QT interval, hearts were paced at 80, 120 and 240 beats
min71 for 1 min, a time sucient to account for the eects
of restitution on the QT interval. In the event that the
pacing protocol was interrupted by the occurrence of
tachyarrhythmias, the pacing duration was extended such
that each heart was paced at a constant rate for at least
1 min. QT intervals were also measured during perfusion
with 3 and 4 mM [K+] buer at a pacing rate of 50 beats
min71 or during spontaneous junctional rhythm (depending
on which rate was greater).
Hearts then were assigned to receive either continued
infusion with vehicle control, dofetilide at successively
increasing concentrations of 3 and 30 nM, or tedisamil at
concentrations of 0.3 mM, followed by 3 mM. Drug
solutions were made up at 60 times the desired
concentration and infused at 1/60th of the coronary ¯ow
rate into a sidearm on the perfusion apparatus. The
protocol described above was repeated at each concentra-
tion of the drug. Thus, each heart was treated with two
test concentrations of vehicle control, dofetilide or
tedisamil.
Experimental protocol for heart rate response studies
In a separate group of hearts, the rate-dependent and pause-
dependent proarrhythmic actions of dofetilide and tedisamil
were explored. Rabbit isolated hearts were set up as
described above. Perfusate [K+] was maintained at 4 mM
throughout this protocol. Hearts were paced for 20 min at
each of 50, 100, 200 and 50 beats min71, successively. Pauses
were inserted in the basic pacing train at various times to
assess the occurrence of pause-dependent torsades de pointes
(see below for de®nition). Every 10 min, three pauses were
inserted in the basic train. In addition, three pauses were
inserted within the ®rst minute at each new pacing rate. The
duration of the pause varied between 2 ± 6 s, depending on
the rate of the spontaneously junctional rhythm of the heart.
In this way, the spontaneous occurrence of torsades de
pointes could be assessed during the basic pacing protocol
and the occurrence of pause-dependent torsades de pointes
could be assessed by introducing a pause in cardiac activity.
Hearts were assigned to treatment with vehicle control,
30 nM dofetilide, or 3 mM tedisamil. Infusions were carried
out as described above. QT intervals were measured 19 min
after commencing pacing at each rate (i.e., just before
introducing the ®nal pause in cardiac activity at each pacing
rate).
Assessment of serum [K+] in conscious rabbits
A blood sample was obtained from the marginal ear vein of
35 rabbits before starting the protocol. Blood samples (1 ml)
were heparinised and spun at 40006g for 10 min. The [K+]
of the plasma was measured using a potassium selective
electrode (Model 16.40, Instrumentation Laboratory, Lex-
ington, MA, U.S.A.).
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Drugs
Tedisamil was obtained from Kali-Chemi (Hanover,
Germany) and dofetilide was obtained from P®zer
(Sandwich, U.K.). The test concentrations of tedisamil
were selected on the basis of previous studies in our
laboratory (Chi et al., 1996; Friedrichs et al., 1998), as well
as others (Tsuchihashi & Curtis, 1991), which demonstrated
that tedisamil had antiarrhythmic actions over this
concentration range (0.3 ± 3 mM) in vitro and in vivo. The
lowest concentration of dofetilide (3 nM) was selected on
the basis of a literature report that demonstrated the
antiarrhythmic activity of this drug in man (Echt et al.,
1995). The highest concentration of dofetilide was intended
to be supra-maximal, such that a high incidence of torsades
de pointes could be observed (i.e., 30 nM dofetilide served
as a positive control).
Definition of end points
The QT interval was measured from the Q wave, or the
onset of the R wave if a Q wave was not present, to the
point where a tangent drawn to the steepest portion of the
T wave crossed the isoelectric line. Other less conventional
measures of repolarization time were obtained from the
ECG. The QTa interval was measured from the Q wave, or
the onset of the R wave if a Q wave was not present, to
the peak of the T wave. The interval between the peak and
the end of the T wave (QTa-e) was measured as an
indicator of the homogeneity of the repolarization process
(Antzelevitch et al., 1999). All of the above noted measures
were made from lead II of the ECG from three successive
beats.
For the purposes of this study, torsades de pointes was
de®ned as a `polymorphic ventricular tachycardia character-
ized by an onset with abnormal QT-prolongation and/or
abnormal TU complexes, the electrocardiographic con®gura-
tion of a progressively changing ventricular axis, and
spontaneous termination with the exception of rare degen-
eration into ventricular ®brillation', as recently described by
Eckardt et al. (1998). A minimum of four beats was required
to diagnose torsades de pointes. As the ECG morphology of
torsades de pointes is known to depend on the lead
considered, monitoring multiple ECG leads was necessary
to ensure accurate diagnosis. In the heart rate response
studies, pause-dependent torsades de pointes was said to
occur if torsades de pointes occurred within 1 min after a
pause in cardiac activity.
Statistics
All data are summarized as the mean+s.e.mean, n=4±7 in
each group. At the higher test concentration of each drug
and at low pacing rates, QT intervals could not be
measured due to the occurrence of premature ventricular
beats and torsades de pointes. Repeated measures analysis
of variance (ANOVA) was used to test for statistical
signi®cance and a Tukey test was used to detect dierences
between groups. All statistical tests were two tailed and a
value of P50.05 was considered statistically signi®cant. The
incidence of torsades de pointes was analysed using a Chi
Square analysis.
Results
QT prolonging and proarrhythmic actions of dofetilide
and tedisamil
The QT interval was longer at lower pacing rates (P50.05)
before drug treatment in all groups (Figure 1). Both
dofetilide and tedisamil exacerbated this eect and QT
intervals were prolonged in a concentration- and reverse
rate-dependent fashion relative to vehicle control (Figure 1).
The QTa-e interval did not vary with heart rate in vehicle
treated hearts but was prolonged in a concentration- and
reverse rate-dependent fashion by both dofetilide and
tedisamil (Figure 2). Drug-induced QT prolongation was
not in¯uenced by perfusion with low [K+] buer (3 mM [K+],
Figure 3).
The incidence of dofetilide and tedisamil-induced torsades
de pointes was concentration-dependent (Figure 4, Table 1).
Torsades de pointes was observed in 1/7 hearts treated with
3 nM dofetilide and 0/7 hearts treated with 0.3 mM tedisamil.
In hearts treated with either 30 nM dofetilide or 3 mM
tedisamil, torsades de pointes was observed in 7/7 hearts
(P50.05 vs vehicle control). In drug-treated hearts, torsades
de pointes occurred at various times during the 20 min
observation period at 4 mM [K+]. During the 5 min
observation period in hearts perfused with 3 mM [K+],
torsades de pointes occurred in 3/7 hearts treated with either
30 nM dofetilide or 3 mM tedisamil. Perfusion of hearts with
low [K+] buer (3 mM) precipitated torsades de pointes in
two hearts treated with 30 nM dofetilide in which it did not
occur during perfusion with normal [K+] buer (Table 1).
Torsades de pointes was not observed in vehicle-treated
hearts and ventricular ®brillation was not observed in any
group.
QT prolonging and proarrhythmic actions of dofetilide
and tedisamil; effect of heart rate
The QT interval exhibited reverse-rate dependent properties
such that QT intervals were longer at low pacing rates
(P50.05, Figure 5). Both dofetilide and tedisamil
exacerbated this phenomenon and QT intervals were
prolonged in a reverse rate-dependent fashion (Figure 5).
The QTa-e interval was prolonged only at a pacing rate of
50 beats min71, whereas the QT interval was prolonged at
all pacing rates relative to vehicle control (Figure 5). In
this way the QTa-e interval was more speci®cally
associated with the occurrence of torsades de pointes
(r=0.91, P50.01).
In parallel to the reverse rate-dependent actions of both
drugs on the QT interval, the incidence of torsades de pointes
was greater at lower pacing rates (Table 2). At a pacing rate
of 50 beats min71 all hearts treated with either 3 mM tedisamil
or 30 nM dofetilide exhibited torsades de pointes. The ®rst
time hearts were paced at 50 beats min71 torsades de pointes
was observed in 4/5 hearts in each drug-treated group.
During pacing at 50 beats min71 the second time, torsades de
pointes was observed in the one heart in each drug-treated
group in which it was not observed during the ®rst pacing
episode at this rate. Thus, the overall incidence of torsades de
pointes in drug-treated hearts was 5/5 (P50.05 vs vehicle
control).
British Journal of Pharmacology vol 132 (7)
Tedisamil-induced torsades de pointesT.D. Barrett et al 1495
Once torsades de pointes occurred spontaneously it could
commonly be provoked by a pause in cardiac activity and, in
addition, torsades de pointes could be provoked after a pause
in cardiac activity at pacing rates where it did not occur
spontaneously. Torsades de pointes was observed in 1/5
hearts treated with 30 nM dofetilide and 2/5 hearts treated
with 3 mM tedisamil when hearts were paced at 200 beats
min71 (Table 2, Figure 6). These pause-dependent events
occurred following a stepwise increase in the pacing rate from
100 to 200 beats min71. Spontaneous torsades de pointes was
Figure 2 The eect of vehicle control (top), dofetilide (middle) and
tedisamil (bottom) on the QTa-e interval in rabbit isolated hearts
paced at 80, 120 and 240 beats min71. Each point represents the
mean+s.e.mean, n=5±7. The QTa-e interval was measured from
lead II. The * denotes statistical signi®cance vs vehicle control at
P50.05 (repeated measures ANOVA followed by a Tukey test for
dierences).
Figure 1 The eect of vehicle control (top), dofetilide (middle) and
tedisamil (bottom) on the QT interval in rabbit isolated hearts paced
at 80, 120 and 240 beats min71. Each point represents the
mean+s.e.mean, n=5±7. The QT interval was measured from lead
II. The * denotes statistical signi®cance vs vehicle control at P50.05
(repeated measures ANOVA followed by Tukey test). The # denotes
statistical signi®cance from the lower concentration of the same
agent.
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not observed at a pacing rate of 200 beats min71 nor could it
be precipitated by a pause in cardiac activity after pacing for
10 min at this rate. The proarrhythmic actions of dofetilide
and tedisamil were re-established upon reducing the pacing
rate to 50 beats min71. Torsades de pointes was not observed
in vehicle controls and ventricular ®brillation was not
observed in any group.
Serum potassium concentration in conscious rabbits
Serum [K+] was measured in conscious rabbits to ensure that
the [K+] studied in vitro was relevant to that observed in vivo.
The serum [K+] in rabbits averaged 4.2+0.1 mM (n=35,
range 2.7 ± 6.6 mM).
Discussion
The QT prolonging actions of dofetilide and tedisamil were
associated with a similar risk of torsades de pointes. Both the
QT prolongation and the proarrhythmic actions of dofetilide
and tedisamil were concentration- and reverse rate-depen-
dent. Thus, there was a high incidence of torsades de pointes
in hearts treated with either 30 nM dofetilide or 3 mM
tedisamil under conditions of bradycardia. Tedisamil's pro®le
might be particularly insidious as this drug has bradycardic
actions and could therefore precipitate the very conditions
under which its proarrhythmic actions are manifested. The
data also suggest that the proarrhythmic actions of dofetilide
were exacerbated by perfusion with a low [K+] buer.
The concentrations tested in the present study have been
demonstrated to prolong cardiac action potentials, prolong
the QT interval of the ECG and have antiarrhythmic actions
in vitro and in vivo (Beatch et al., 1991; Tsuchihashi & Curtis,
1991; Chi et al., 1996; Wallace et al., 1995; Friedrichs et al.,
1996; 1998). Our previous studies in the rabbit isolated heart
preparation demonstrated the anti®brillatory eects of
tedisamil at a concentration of 3 mM (Chi et al., 1996).
Similarly, a concentration of *0.6 mM has been documented
to be eective in our canine sudden death model (Friedrichs
et al., 1998). The concentrations tested in the present study
are therefore directly relevant to the observed antiarrhythmic
actions of tedisamil and the use of this agent to prevent or
revert cardiac arrhythmias is likely to be associated with a
risk of torsades de pointes in man. The doses used to treat
angina pectoris in man are somewhat lower than those
demonstrated to have antiarrhythmic actions in animal
models. Despite the lower dose of tedisamil, the QTc interval
Figure 3 The eect of vehicle control, dofetilide and tedisamil on
the QT interval in rabbit isolated hearts during perfusion with 3 or
4 mM [K+]. Mean QT intervals+s.e.mean, n=4±7 during perfusion
with vehicle control, dofetilide (C1=3 nM and C2=30 nM) or
tedisamil (C1=0.3 mM and C2=3 mM). PD denotes pre-drug values.
QT intervals were measured from lead II. The group mean
ventricular rate was 50+2 beats min71. The * denotes statistical
signi®cance vs vehicle control at P50.05 (repeated measures
ANOVA followed by a Tukey test for dierences).
Figure 4 Representative ECG record showing torsades de pointes
induced in the rabbit isolated heart by 3 mM tedisamil. Leads V1, V3,
V5 and II are shown from top to bottom, respectively. The vertical
divisions are 1 s apart and the horizontal divisions represent 0.5 mV.
The perfusate [K+] was 4 mM.
Table 1 Incidence of dofetilide and tedisamil-induced torsades de pointes in rabbit isolated hearts
Vehicle Dofetilide Dofetilide Tedisamil Tedisamil
Treatment control (3 nM) (30 nM) (0.3 mM) (3 mM)
Overall incidence 0/7 1/7 7/7* 0/7 7/7*
[K+] 4 mM, 20 min 0/7 1/7 5/7* 0/7 7/7*
[K+] 3 mM, 5 min 0/7 1/7 3/7 0/7 3/7
Results are presented as the group incidence of torsades de pointes. The overall incidence summarizes the occurrence of torsades de
pointes during both observation periods. For vehicle control, data are summarized for the entire duration of the experiment in a single
column. Statistical signi®cance vs vehicle control was determined using a Chi Square test at a signi®cance level of P50.05.
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was prolonged in clinical trials (Bargheer et al., 1994; Fox et
al., 2000). If prolongation of the QTc interval is taken as a
valid measure of the risk of torsades de pointes, then the data
suggest that there is a risk of torsades de pointes with
tedisamil at doses used to treat angina pectoris.
It is noteworthy that the QTc interval was not prolonged
at eective doses (3 mg kg71 BID p.o.) in our canine sudden
death model (Friedrichs et al., 1998). Torsades de pointes
also was not observed in this study. Torsades de pointes also
was not observed in our previous in vitro study with
tedisamil, despite perfusion of rabbit isolated hearts with a
low [K+] buer (2.5 mM, Chi et al., 1996). In the latter study,
hearts were paced faster than their intrinsic sinus rate. One
possible explanation for the apparently incongruent observa-
tions is that the proarrhythmic actions of tedisamil are
bradycardia dependent (as demonstrated in the present
study).
The QT prolonging actions of dofetilide and tedisamil were
reverse rate-dependent in keeping with previous observations
(Sanguinetti & Jurkiewicz, 1990). Dofetilide is a potent and
selective blocker of the rapidly activating component of the
delayed recti®er K+ current (IKr). Reverse rate-dependent
Figure 5 The eects of vehicle control, dofetilide and tedisamil on
the QT interval (top) and QTa-e interval (bottom) in rabbit isolated
hearts paced at 50, 100, 200 and 50 beats min71. Each point
represents the mean+s.e.mean, n=4±5. Both intervals were
measured from lead II. The * denotes statistical signi®cance vs
vehicle control at P50.05 (repeated measures ANOVA followed by a
Tukey test for dierences).
Table 2 The eect of heart rate on the incidence of dofetilide and tedisamil-induced torsades de pointes in the rabbit isolated heart
Treatment 50 beats min71 100 beats min71 200 beats min71 50 beats min71
Spontaneous torsades de pointes
Vehicle control 0/5 0/5 0/5 0/5
30 nM Dofetilide 4/5* 1/5 0/5 4/5*
3 mM Tedisamil 4/5* 1/5 0/5 4/5*
Pause-dependent torsades de pointes
Vehicle control 0/5 0/5 0/5 0/5
30 nM Dofetilide 3/5 2/5 1/5 3/5
3 mM Tedisamil 3/5 2/5 2/5 4/5*
Results are presented as the group incidence of torsades de pointes at the pacing rates indicated. Pause-dependent torsades de pointes
refers to the occurrence of torsades de pointes following a pause in cardiac activity (see text for de®nitions). Statistical signi®cance vs
vehicle control was tested using a Chi Square test with a signi®cance level of P50.05.
Figure 6 Representative ECG record showing pause-dependent
torsades de pointes induced in the rabbit isolated heart by 3 mM
tedisamil. Leads V1, V3, V5 and II are shown from top to bottom,
respectively. The vertical divisions are 1 s apart and the horizontal
division represent 0.5 mV. The perfusate [K+] was 4 mM. Note the
presence of AV block, which is characterized by the dissociation
between P waves and the QRS complex.
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action potential and QT interval prolongation are the
hallmarks of drugs with this pro®le (Hondeghem & Snyders,
1990). The similarity in the actions of dofetilide and tedisamil
suggest that tedisamil's QT prolonging and proarrhythmic
actions are mediated by blockade of IKr. While this might
explain the observed eects, it is by no means certain. As
noted earlier, tedisamil is known to block a number of
cardiac ion currents, any of which might contribute to the
observed proarrhythmic eects.
The proarrhythmic actions of dofetilide tended to be
exacerbated by perfusion with low [K+] buer (3 vs 4 mM).
Low [K+] concentrations are known to potentiate the
blockade of IKr produced by dofetilide (Yang & Roden,
1996; Du et al., 1997). In keeping with this, torsades de
pointes occurred in two hearts treated with 30 nM dofetilide
during perfusion with 3 mM [K+] in which torsades de
pointes did not occur during perfusion with 4 mM [K+].
The QTa-e interval was measured in an attempt to assess
drug-induced changes in T wave morphology and to relate
these changes to the occurrence of torsades de pointes. It has
been suggested that changes in T wave morphology and/or
the appearance of a U wave may be more predictive of
torsades de pointes than QT (or QTc) prolongation per se
(Jackman et al., 1988; Antzelevitch et al., 1999). The QTa-e
interval was prolonged in a concentration- and reverse rate-
dependent fashion by both drugs, but was independent of
pacing rate in vehicle controls. Moreover, prolongation of the
QTa-e interval was associated with a high incidence of
torsades de pointes. Thus, this measure might prove to be a
useful, quantitative measure of changes in T wave morphol-
ogy. Further studies are required to assess the sensitivity,
speci®city and utility of this measure.
Torsades de pointes occurred commonly after a pause in
cardiac activity at low pacing rates and could be precipitated
after a pause in cardiac activity during a rate transition at
higher pacing rates. Such pause-dependent torsades de
pointes might be clinically important (Jackman et al., 1988).
A pause in cardiac activity could occur after a premature
beat or may also occur in patients with sinus node
dysfunction. Patients converted from atrial ®brillation are
known to have sinus node dysfunction and antiarrhythmic
drugs can exacerbate this dysfunction. In addition, conver-
sion of atrial ®brillation is associated with sudden changes in
ventricular rate. It is not surprising, therefore, that torsades
de pointes can occur quickly after conversion of atrial
®brillation to sinus rhythm with Class III drugs (e.g., Kowey
et al., 1996; Frost et al., 1997). The model described in the
present study oers the advantage of allowing such pause-
dependence to be examined.
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